Amgen’s cholesterol-lowering drug Repatha gets U.S. approval
Thousand Oaks-based biotech giant Amgen won U.S. approval for its powerful cholesterol-lowering drug Repatha for certain patients, making it the second in a new class of treatments to come to market, Bloomberg News reported Aug. 27. The Food and Drug Administration cleared Repatha for people with hard-to-treat levels of bad cholesterol, according to a statement Read More →
Read More →
Atara Biotherapeutics angles for $92M, but jobs are scarce
Atara is among a new breed of “virtual” biotech startups. Such firms operate with barebones staff and outsource research and manufacturing operations to contract organizations. They are becoming increasingly common as investors seek to mitigate the huge risks of bringing drugs to market, a process that can cost as much as $1.8 billion, according to industry estimates.
Read More →Pharma shakeups put pressure on top brass at Amgen to perform
With activist investor Bill Ackman pushing to buy Botox maker Allegran in a bid with upstart Valeant and restructurings under way at pharma giants GlaxoSmithKline, Eli Lilly & Co. and Novartis, it’s logical to question whether biotech giant Amgen will be next. So far the answer seems to be “not yet” — with one big Read More →
Read More →Amgen pays $290M to exit osteoporosis drug deal
Amgen will pay $290 million to end its collaboration with British drugmaker GlaxoSmithKline to commercialize the osteoporosis drug denosumab in certain markets outside the U.S.
Read More →Ceres to plow $23M raise into sorghum tests
Thousand Oaks-based energy crop firm Ceres has raised $23 million that it hopes will help it to break even as it continues testing its seeds in Brazil.
Read More →
Sponsored content:
2015-2016 Giving Guide
